LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

Treace Medical Concepts Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents

December 19, 2022 | Last Trade: US$9.36 0.07 -0.74

PONTE VEDRA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), is pleased to announce that the United States Patent and Trademark Office has granted to the Company U.S. Patent Nos. 11,497,528 and 11,523,845. The two new patents relate to novel methods of performing bunion surgery utilizing a bone positioning device. These patents strategically enhance Treace Medical’s comprehensive patent coverage on instrumented bunion correction techniques. The patents expand on a portfolio stemming from Treace Medical’s pioneering development work in the field, with priority dating back to 2014, and relate to Treace Medical’s Lapiplasty® 3D Bunion Correction™ system.

Treace Medical actively protects its innovations through patenting and is gratified that the United States Patent and Trademark Office and patent agencies worldwide continue to recognize the novelty of Treace Medical’s contributions to the field. The Company has a global portfolio of 50 granted patents, including 40 in the US, and 80 pending patent applications, including over 40 pending US patent applications. Additional details on Treace Medical’s patent coverage can be found at www.treace.com/patents.

“We are pleased that the Patent Office continues to recognize the innovative advances made by Treace Medical by granting these additional patents,” said John T. Treace, CEO, Founder and Board Member of Treace Medical. “Our intellectual property is a critical component in enabling the advancement of bunion patient care and allows Treace Medical to continue investing in solutions that benefit patients,” Mr. Treace added.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace Medical recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page